Patent ID: 7122187

Claim:
A method of treating an autoimmune disorder comprising administering a therapeutically effective amount of a humanized antibody or antigen binding fragment that specifically binds CD40 ligand that contains a variable light sequence which comprises the amino acid sequence encoded by SEQ ID NO: 24 or SEQ ID NO: 25 and a variable heavy sequence which comprises the amino acid sequence encoded by the nucleic acid sequence SEQ ID NO: 26, wherein said autoimmune disorder is selected from the group consisting of diabetes mellitus, psoriasis, autoimmune glomerulonephritis, autoimmune hemolytic anemia, Addison's disease, autoimmune oophoritis, autoimmune orchitis, autoimmune polyendocrine failure, Behcet' disease, Berger's disease; Buerger's disease, bullous pemphigus, celiac sprue, Graves disease, Goodpasture's Syndrome, Hashimato's thyroiditis, chronic active hepatitis, chronic progressive hepatitis, idiopathic thrombocytopenia purpura, Job's syndrome, psoriatic arthritis, rheumatoid arthritis, Kawasaki's disease, multiple sclerosis, myasthenia gravis, pemphigoid, pemphigus, pemphigus erythematosus, pemphigus foliaceus, pemphigus vulgaris, polymyalgia rheumatica, pulmonary fibrosis, Reiter's syndrome, Reidel's thyroiditis, rheumatic fever, sarcoidosis, Sezary syndrome; Scleroderma, ulcerative colitis, autoimmune hemolytic anemia, Felty's syndrome, systemic lupus erythematosus, discoid lupus erythematosus, autoimmune polyarteritis nodosa, Caplan's syndrome, Crohn's disease, psoriasis, Sjogren's syndrome, Crest syndrome, and Wiscott-Aldrich syndrome.